MedPath

Percutaneous Transhepatic Cholangiography (PTHC) in Acute Cholecystitis and Clinical Outcomes

Withdrawn
Conditions
Cholecystitis, Acute
Elderly Infection
Drain Abscess
Registration Number
NCT03087747
Lead Sponsor
University of Split, School of Medicine
Brief Summary

In a setting of acute cholecystitis (AC) one of the treatment option is percutaneous transhepatic cholangiography (PTHC) drainage. The goal of current study is to evaluate some radiology aspects and correlate with clinical patient outcomes in patients with acute cholecystitis severity grade III (presented as acute cholecystitis with organ dysfunction).

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • clinical markers of acute cholecystitis
  • diagnosis confirmed with some imaging technique: computed tomography (CT), ultrasound (US).
Exclusion Criteria
  • clinical diagnosis was not confirmed with imaging.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
C-reactive protein (CRP)Up to 8 weeks.

C-reactive protein (CRP) is a protein found in blood plasma, whose levels rise in response to inflammation.

Secondary Outcome Measures
NameTimeMethod
White blood cells (WBCs) countUp to 8 weeks.

White blood cells (WBCs) are the cells of the immune system. During inflammation White blood cell level rise.

Drainage duration (expressed in days)Up to 16 weeks.

The drain which is placed in gallbladder during Percutaneous transhepatic cholangiography (PTHC) remains there until resolving clinical parameters of acute cholecystitis.

Trial Locations

Locations (1)

University of Split, School of Medicine

🇭🇷

Split, Croatia

University of Split, School of Medicine
🇭🇷Split, Croatia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.